Joel P. Berger

15.6k citations

93 papers · 11.8k indexed · 5 hit papers · h-index 46

Molecular Biology top 0.5%
Physiology top 0.2%
Epidemiology top 0.5%
Endocrinology, Diabetes and Metabolism top 0.5%
Biochemistry top 0.2%

Co-authors: David E. Moller Taro E. Akiyama Peter T. Meinke Alex Elbrecht Philipp E. Scherer John A. Wagner Karen L. MacNaul Tom Doebber
Topics: Peroxisome Proliferator-Activated Receptors (61 papers)Adipose Tissue and Metabolism (44 papers)Metabolism, Diabetes, and Cancer (28 papers)
Cited by: Biochemistry Physiology Molecular Biology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Nature Medicine
Partner nations: United States Canada Japan

In The Last Decade

Joel P. Berger

93 papers receiving 11.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Mechanisms of Action of PPARs

2002 2.1k citations Joel P. Berger, David E. Moller profile →
Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity

2004 978 citations Tom Doebber, Joel P. Berger et al. Journal of Biological Chemistry profile →
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors

2006 813 citations Joel P. Berger, Jorge Plutzky et al. profile →
Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian Cells

2004 647 citations Qiang Tian, Mao Mao et al. Molecular & Cellular Proteomics profile →
PPARs: therapeutic targets for metabolic disease

2005 587 citations Joel P. Berger, Taro E. Akiyama et al. profile →

Peers

Countries citing papers authored by Joel P. Berger

Since Specialization

Citations

This map shows the geographic impact of Joel P. Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel P. Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel P. Berger more than expected).

Fields of papers citing papers by Joel P. Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel P. Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel P. Berger. The network helps show where Joel P. Berger may publish in the future.

Co-authorship network of co-authors of Joel P. Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Joel P. Berger. A scholar is included among the top collaborators of Joel P. Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel P. Berger. Joel P. Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice 2017 ·Endocrinology Diabetes & Metabolism ·Joel P. Berger,Ranabir SinhaRoy,Alessandro Pocai,Theresa M. Kelly,Giovanna Scapin,Ying‐Duo Gao,(unknown),Joseph K. Wu,George J. Eiermann,Shiyao Xu,Xiaoping Zhang,Daniel Tatosian,Ann E. Weber,Nancy A. Thornberry,Richard D. Carr	67
2	Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs 2011 ·Molecular Pharmacology ·Jun‐ichi Eiki,Yasufumi Nagata,Mayumi Futamura,(unknown),Tomoharu Iino,T. Nishimura,Masato Chiba,Sumika Ohyama,(unknown),Kenji Fujii,Hideka Hosaka,(unknown),(unknown),Tomoyuki Ohe,Songnian Lin,Ronald B. Langdon,Joel P. Berger	25
3	Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities 2010 ·Bioorganic & Medicinal Chemistry Letters ·Haifeng Tang,(unknown),Zhe Feng,(unknown),Lihu Yang,Dorothy Levorse,Karen Owens,Taro E. Akiyama,Raynald Bergeron,Gino Castriota,Thomas W. Doebber,Kenneth Ellsworth,Michael E. Lassman,Li Cai,Margaret Wu,Bei B. Zhang,Kevin T. Chapman,Sander G. Mills,Joel P. Berger,Alexander Pasternak	13
4	Proangiogenic Contribution of Adiponectin toward Mammary Tumor Growth In vivo 2009 ·Clinical Cancer Research ·Shira Landskroner-Eiger,Bin‐Zhi Qian,Eric S. Muise,Andrea R. Nawrocki,Joel P. Berger,Eugene J. Fine,Wade Koba,Yingfeng Deng,Jeffrey W. Pollard,Philipp E. Scherer	122
5	Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo 2009 ·European Journal of Pharmacology ·Heather Zhou,Chen‐Ni Chin,Margaret Wu,Weihua Ni,Shuo Quan,Franklin Liu,Qing Dallas-Yang,Kenneth Ellsworth,Thu Ho,Aiwu Zhang,(unknown),Jing Li,Kevin T. Chapman,William R. Strohl,Cai Li,I‐Ming Wang,Joel P. Berger,Zhiqiang An,Bei B. Zhang,Guoqiang Jiang	28
6	Preliminary report: pharmacologic 11β-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet 2009 ·Metabolism ·Magalie Berthiaume,Mathieu Laplante,William T. Festuccia,Joel P. Berger,Rolf Thieringer,Yves Deshaies	15
7	Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Hong C. Shen,Fa‐Xiang Ding,Qiaolin Deng,Suoyu Xu,Hsuan-Shen Chen,Xinchun Tong,Vincent Tong,Xiaoping Zhang,Yuli Chen,Gaochao Zhou,Lee-Yuh Pai,Magdalena Alonso‐Galicia,Bei Zhang,Sophie Roy,James R. Tata,Joel P. Berger,Steven L. Colletti	22
8	Adipose Fibroblast Growth Factor 21 Is Up-Regulated by Peroxisome Proliferator-Activated Receptor γ and Altered Metabolic States 2008 ·Molecular Pharmacology ·Eric S. Muise,B. Azzolina,(unknown),Mohamed El-Sherbeini,Yejun Tan,Xiling Yuan,James Mu,John R. Thompson,Joel P. Berger,Kenny K. Wong	245
9	Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARγ partial agonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·James F. Dropinski,Taro E. Akiyama,Monica Einstein,Bahanu Habulihaz,Tom Doebber,Joel P. Berger,Peter T. Meinke,(unknown)	56
10	(2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents 2005 ·Bioorganic & Medicinal Chemistry Letters ·Hiroo Koyama,(unknown),Daniel J. Miller,Joel P. Berger,Karen L. MacNaul,Pei-Ran Wang,Marc C. Ippolito,Samuel D. Wright,Arun K. Agrawal,David E. Moller,Soumya P. Sahoo	15
11	PPAR ligands: Potential therapies for metabolic syndrome 2005 ·Current Diabetes Reports ·Taro E. Akiyama,Peter T. Meinke,Joel P. Berger	46
12	Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian Cellsbreakdown → 2004 ·Molecular & Cellular Proteomics ·Qiang Tian,(unknown),Mao Mao,(unknown),(unknown),Michelle J. Doyle,Eugene C. Yi,Hongyue Dai,Vésteinn Thórsson,Jimmy K. Eng,David R. Goodlett,Joel P. Berger,Bert Gunter,(unknown),Roland Stoughton,Ruedi Aebersold,Steven Collins,William A. Hanlon,Leroy Hood	647
13	A high-capacity assay for PPARγ ligand regulation of endogenous aP2 expression in 3T3-L1 cells 2004 ·Analytical Biochemistry ·G M Thompson,(unknown),Chhabi Biswas,(unknown),Joel P. Berger,Linda Kelly	40
14	MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activities 2004 ·Biochemical and Biophysical Research Communications ·Thomas W. Doebber,Linda Kelly,Gaochao Zhou,Roger Meurer,Chhabi Biswas,Ying Li,Margaret Wu,Marc C. Ippolito,Yu‐Sheng Chao,Pei-Ran Wang,Samuel D. Wright,David E. Moller,Joel P. Berger	26
15	Aryloxazolidinediones: identification of potent orally active PPAR dual α/γ agonists 2003 ·Bioorganic & Medicinal Chemistry Letters ·Ranjit C. Desai,(unknown),(unknown),Hiroo Koyama,E. Joseph Metzger,(unknown),Karen L. MacNaul,Thomas W. Doebber,Joel P. Berger,Kwan Leung,Ronald B. Franklin,David E. Moller,James V. Heck,Soumya P. Sahoo	18
16	Dual Roles for Lipolysis and Oxidation in Peroxisome Proliferation-Activator Receptor Responses to Electronegative Low Density Lipoprotein 2003 ·Journal of Biological Chemistry ·Ouliana Ziouzenkova,Liana Asatryan,(unknown),Gabriela Orasanu,Stéphane Perrey,(unknown),Tom Hassell,Taro E. Akiyama,Joel P. Berger,Alex Sevanian,Jorge Plutzky	52
17	Activation of Peroxisome Proliferator-Activated Receptor γ Does Not Inhibit IL-6 or TNF-α Responses of Macrophages to Lipopolysaccharide In Vitro or In Vivo 2000 ·The Journal of Immunology ·Rolf Thieringer,Judy Fenyk‐Melody,(unknown),(unknown),Patricia A. Detmers,(unknown),(unknown),David E. Moller,Samuel D. Wright,Joel P. Berger	170
18	Inhibition of Adipocyte Differentiation by HIV Protease Inhibitors 1999 ·The Journal of Clinical Endocrinology & Metabolism ·Bei Zhang,Karen L. MacNaul,Deborah Szalkowski,Zhihua Li,Joel P. Berger,David E. Moller	134
19	L-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ 1999 ·Journal of Biological Chemistry ·Alex Elbrecht,Yuli Chen,Alan Adams,Joel P. Berger,Patrick R. Griffin,(unknown),Bei Zhang,John G. Menke,Gaochao Zhou,Roy G. Smith,David E. Moller	92
20	Carboxyalkyl dipeptides with atrial natriuretic factor potentiating and antihypertensive activity 1989 ·Journal of Medicinal Chemistry ·Martin F. Haslanger,Edmund J. Sybertz,Bernard R. Neustadt,Elizabeth M. Smith,Terry L. Nechuta,Joel P. Berger	12

About Joel P. Berger

Joel P. Berger is a scholar working on Biochemistry, Physiology and Molecular Biology, having authored 93 papers that have together received 11.8k indexed citations. Recurring topics across this work include Peroxisome Proliferator-Activated Receptors (61 papers), Adipose Tissue and Metabolism (44 papers) and Metabolism, Diabetes, and Cancer (28 papers). The work is most often cited by research in Biochemistry (1.1k citations), Physiology (3.8k citations) and Molecular Biology (7.5k citations). Joel P. Berger has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include David E. Moller, Taro E. Akiyama, Peter T. Meinke, Alex Elbrecht, Philipp E. Scherer, John A. Wagner, Karen L. MacNaul, Tom Doebber, Michael W. Rajala and Margaret Wu. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact